Loading...
•
Dec 31, 2024
UroGen Q4 2024 Earnings Report
UroGen reported solid Q4 2024 results, with JELMYTO revenue growing 5% year-over-year, while the company advanced its oncology pipeline.
Key Takeaways
UroGen's Q4 2024 revenue reached $24.6 million, reflecting a 5% year-over-year increase driven by higher JELMYTO demand. The company posted a net loss of $37.5 million due to increased R&D and SG&A expenses. JELMYTO continues to see growth in new patient starts and prescribers, and UroGen remains focused on advancing its UGN-102 NDA submission and pipeline assets.
JELMYTO revenue grew 5% year-over-year to $24.6 million.
Net loss widened to $37.5 million from $26.0 million in Q4 2023.
Operating expenses increased due to higher R&D and SG&A investments.
Cash and cash equivalents stood at $241.7 million as of December 31, 2024.
Revenue by Segment
Forward Guidance
UroGen expects continued revenue growth for JELMYTO in 2025 while focusing on the FDA review of UGN-102 and further advancing its pipeline.
Positive Outlook
- 2025 JELMYTO revenue expected to grow 8-12% to $94-$98 million.
- FDA PDUFA decision for UGN-102 expected by June 13, 2025.
- Cash reserves remain strong at $241.7 million.
- Continued growth in new prescribers and patient starts for JELMYTO.
- Advancing clinical trials for next-generation urothelial cancer treatments.
Challenges Ahead
- Net losses are expected to continue due to high R&D and SG&A costs.
- Increased financing expenses related to the RTW Investments obligation.
- Regulatory risks remain for the approval of UGN-102.
- Competitive pressures in the urothelial cancer treatment market.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...